Prescribing Information: Mounjaro (tirzepatide)
Subgroup analyses for patients pre-existing conditions As reported in a previously published article 26 , EASO identified several subgroups of patients with pre-existing comorbid conditions (Supplementary Table 3)
In the OASIS 4 trial, a Phase 3 study (large, late-stage human trials that decide whether a medication is approved), adults taking the 25 mg tablet lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on a placebo
With 70% of your stomach gone whats left is the shape of a banana, that cant really hold food anymore, so it pushes through way faster
Providers should review pregnancy intentions, contraception options, discontinuation timing, and plans for glycemic management if pregnancy occurs